PTC Therapeutics (NASDAQ:PTCT)

CAPS Rating: 2 out of 5

Caps

How do you think PTCT will perform against the market?

Add Stock to CAPS Watchlist

All Players

29 Outperform
15 Underperform
 

All-Star Players

12 Outperform
9 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top PTCT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TSIF (99.98)
Submitted February 23, 2016

I'm not sure which is more mysterious...1. That the company hasn't chimed in yet with a plan of action well into the day it's stock cratered from an FDA "refuse to file" letter.2. That the company was inept enough to file an application that was so… More

noataluren (< 20)
Submitted May 28, 2014

As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating 2 patients whose baseline data was faulty) in the… More

PTCT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about PTCT.

Recs

0
Member Avatar TMFBiologyFool (86.13) Submitted: 6/19/2018 5:31:18 PM : Outperform Start Price: $35.00 PTCT Score: +24.22

Overreaction to SRPT gene therapy data.

Recs

0
Member Avatar MarkBiotech (33.26) Submitted: 3/7/2018 4:30:35 PM : Outperform Start Price: $27.90 PTCT Score: +54.92

the quick uptake and strong launch of SRPT's Exondy's has shown us how large of a need their is for DMD patients. Despite the public backlash on emflaza's pricing, its launch still continues to be very strong.. Also ataluren's EU sales are progessing nicely.. the eventual approval(despite CRL) for ataluren in the US should give PTCT a good boost in future value.. Guidance for 2018 stands at 260-295M(VS 300M for srpt).. that puts PTCT valuation at 4x 2018 sales which is considered VERY CHEAP.. This valuation is also undermining RG7916 in SMA which has shown robust preliminary data. i could see PTCT double in the near future due to its low valuation.. PT- 60

Recs

0
Member Avatar zzlangerhans (99.62) Submitted: 5/26/2016 5:14:18 PM : Underperform Start Price: $7.88 PTCT Score: -436.72

PTC continues to have its ups and downs since the February crash but I share the view of the FDA that there is no evidence Translarna is effective. I think there's a good chance that CHMP will revoke the conditional approval within the next few months, but the chance that they do not is enough to keep me from shorting the stock. CHMP seems to have a somewhat different mentality about placebos than the FDA. Regardless, one day the truth will finally be apparent to all and PTC will stop diverting valuable and limited resources away from treatments that might actually work.

Leaderboard

Find the members with the highest scoring picks in PTCT.

Score Leader

stainsolution

stainsolution (41.06) Score: +648.37

The Score Leader is the player with the highest score across all their picks in PTCT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stainsolution 41.06 3/1/2016 Outperform 5Y $5.70 +695.96% +47.60% +648.37 0 Comment
portefeuille 98.53 3/1/2016 Outperform 5Y $6.42 +606.70% +48.61% +558.09 0 Comment
wkdkdka84 < 20 6/23/2016 Outperform 5Y $6.98 +550.47% +38.14% +512.32 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. DeathStock 96.62 4/15/2016 Outperform 5Y $7.22 +528.39% +40.05% +488.34 0 Comment
WudoUknow 74.85 2/29/2016 Outperform 5Y $7.84 +478.40% +50.19% +428.21 0 Comment
saxjax 55.79 8/19/2016 Outperform 5Y $8.12 +458.74% +33.40% +425.35 0 Comment
Playa14 < 20 4/6/2017 Outperform 5Y $9.69 +368.21% +23.96% +344.26 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. skyrocket29 64.31 3/9/2017 9/5/2017 Outperform 3M $10.32 +339.63% +23.03% +316.60 0 Comment
NajdorfSicilian 99.75 4/20/2017 Outperform 5Y $11.20 +305.09% +23.63% +281.46 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Prodders 39.96 2/2/2017 Outperform 5Y $13.10 +246.34% +28.08% +218.25 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRBCCapMkts 85.32 6/18/2018 Outperform NS $49.54 -8.42% +5.71% -14.13 0 Comment
TrackJimCramer 85.81 9/17/2015 Underperform 3W $35.94 +26.24% +46.60% +20.36 0 Comment
TrackJimCramer 85.81 1/6/2015 Outperform 3W $51.07 -29.63% -0.59% -29.04 9/17/2015 @ $35.94 0 Comment
TrackDeutscheSec 84.56 9/15/2014 Outperform NS $36.50 +24.30% +46.22% -21.92 0 Comment
TrackWedbush 87.81 7/17/2013 Outperform NS $16.78 +170.38% +73.18% +97.20 0 Comment
TrackCreditSuiss 89.10 7/15/2013 Outperform NS $17.30 +162.25% +73.38% +88.88 0 Comment

Featured Broker Partners


Advertisement